- Sonexa Therapeutics Inc.
- Cerexa Inc.
- Taligen Therapeutics Inc.
- BrainCells Inc.
- Cytogen Corp.
- Bioheart Inc.
- MolMed SPA
- Cell Therapeutics Europe SRL
- Archemix Corp.
- AstraZeneca PLC
- Albireo AB
- Vantia Therapeutics Ltd.
- Pieris Pharmaceuticals Inc.
- Endotis Pharma
- Fujifilm Holdings Corp.
- Fujifilm Toyama Chemical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- CoGenesys Inc.
- Human Genome Sciences Inc.
- Bentley Pharmaceuticals Inc.
- Pfizer Inc.
- Encysive Pharmaceuticals Inc.
- Serenex Inc.
- Biogen Inc.
- Galderma SA
- Galderma Laboratories Inc.
- CollaGenex Pharmaceuticals Inc.
- Dynogen Pharmaceuticals Inc.
- Mitsubishi Chemical Holdings Corp.
- Mitsubishi Tanabe Pharma Corp.
- Helomics Corp.
- Genzyme Corp.
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Schering-Plough Corp.
- AstraZeneca PLC
- Silence Therapeutics PLC
- Takeda Pharmaceutical Co. Ltd.
- Amgen Inc.
- Novartis AG
- Cell Genesys Inc.
- TAP Pharmaceutical Products Inc.
- Abbott Laboratories Inc.
- GlaxoSmithKline PLC
- Amira Pharmaceuticals Inc.
- Sonexa Therapeutics takes in $30mm through first round
- Series B for Taligen Therapeutics to bring in $65mm
- BrainCells gets $30mm in Series B, adds another $20mm
- EUSA to buy Cytogen for $22mm in cash
- Bioheart completes its IPO one year later
- Novuspharma raises $173.45mm with IPO
- MolMed completes €56.2mm IPO on Borsa Italiana
- Philogen files for Italian IPO; withdrawn
- Series D for ReVision Optics leads to $25mm
- AstraZeneca spins out Albireo
- Vantia brings in £19mm with its Series A venture round
- Series B brings in €25mm for Pieris AG
- Endotis Pharma closes its Series B round
- Fujifilm buys 66% stake in Toyama Chemical; later merges it with radiopharmaceuticals division
- Teva moves towards biosimilars through $400mm CoGenesys buy
- Teva eyes Spanish generics market in $337mm Bentley buy
- Pfizer buys Encysive for $191mm in cash
- Pfizer buys Serenex, gaining its Hsp90 program
- Biogen Idec buys Conforma for $150mm plus earn-outs
- Galderma buys CollaGenex for $420mm in cash
- Dynogen to go public in reverse merger with Apex; withdrawn
- Dynogen repositions Mitsubishi Pharma compound
- Dynogen licenses Phase II GI compound from Mitsubishi
- Precision pulls IPO, merges with Oracle to go public; withdrawn
- Genzyme and Isis enter $1.2bn CV collaboration
- Silence Therapeutics and AZ partner again
- AstraZeneca and Silence commence respiratory alliance
- Takeda gets Japanese rights to 13 Amgen compounds
- Takeda to sell GVAX immunotherapy for Cell Genesys; ends
- Abbott and Takeda end TAP joint venture after 30 years
- GSK to develop Amira's FLAP blockers for asthma, CV diseases
- Roche, Amira agree to inflammation drug deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.